The candidate enhancers of HGF and UCHL1 exemplify de novo formed enhancers, i.e., not present at any stage of late B lineage development, while the CCND2 enhancer provides an example of ‘re-commissioned’ super-enhancer, i.e., active in myeloma but not in normal PC. Here, CCND2 is linked to plasma cell myeloma.